Figure 5 | Scientific Reports

Figure 5

From: A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes

Figure 5

SEC analysis. SEC elution profiles of (a) ranibizumab, (b) aflibercept, and (c) bevacizumab at D0 (black) and D7 (blue). Comparison of AUC (%) of peak A and B for samples of (d) aflibercept and (e) bevacizumab from D0 and D7. Ranibizumab (a) only displayed one peak. The data are presented as mean ± SD. For each sample set n = 6. The unpaired Student’s t-test was used for statistical analysis.

Back to article page